Jemperli – the seventh approved drug in the PD-1/PD-L1 inhibitor class – was acquired by GSK as part of its $5.1 billion takeover of Tesaro along with PARP inhibitor Zejula (niraparib ...

Jemperli was the first drug in the class to be approved for front-line use in endometrial cancer last year, based on progression-free survival data from RUBY, but with a restricted label that ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

In Dungeons and Dragons, choosing one of the 14 DnD classes might be the most important decision you can make. D&D classes shape the way you play, allowing you to wield axes, cast spells, or even ...

Teva Pharmaceutical Industries Ltd. ADR-2.66% $19.77B ...